Is the 21-gene recurrence score a cost-effective assay in endocrine-sensitive node-negative breast cancer?

Lamond, Nathan W D; Skedgel, Chris; Younis, Tallal

Lamond, Nathan W D; Skedgel, Chris; Younis, Tallal.

Affiliation

Lamond NW; Department of Medicine of Dalhousie University, Queen Elizabeth II Health Sciences Centre, 457 Bethune Building, 1278 Tower Road, Halifax, NS, B3H 2Y9, Canada.

Expert Rev Pharmacoecon Outcomes Res ; 13(2): 243-50, 2013 Apr.

Article in En | MEDLINE | ID: mdl-23570435

Subject(s)

Breast Neoplasms/genetics; Chemotherapy, Adjuvant/methods; Gene Expression Profiling/methods; Antineoplastic Agents/therapeutic use; Breast Neoplasms/drug therapy; Breast Neoplasms/economics; Cost-Benefit Analysis; Female; Gene Expression Profiling/economics; Humans; Lymph Nodes; Neoplasm Recurrence, Local; Prognosis

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Chemotherapy, Adjuvant / Gene Expression Profiling Type of study: Diagnostic_studies / Guideline / Health_economic_evaluation / Prognostic_studies Limits: Female / Humans Language: En Journal: Expert Rev Pharmacoecon Outcomes Res Journal subject: FARMACOLOGIA Year: 2013 Document type: Article Affiliation country: Canada Country of publication: United kingdom

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google